KDR and neoplasm: On the other hand, VEGFR inhibitory therapy reduces the blood supply to the tumour mainly by blocking tumour angiogenesis, which may affect the tumour immune microenvironment and immune cell activity, thus affecting the efficacy of toripalimab [29, 30].